

Additionally, the restriction requirement included a requirement to elect particular disclosed species. In response, Applicants elect the following species: cholinergic neurons, NGF, and SEQ ID NO. 15. Applicants' election of species is for search purposes only. Applicants respectfully remind the Examiner that upon allowance of a generic claim, all claims properly dependent thereon must be considered. MPEP 809.02(c).

Please enter the following amendments

In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

~~Please cancel, without prejudice, claims 7-9.~~

a¹ 1. **(Amended)** A method of promoting differentiation or survival of a cholinergic neuron, comprising administering a trophic amount of a composition comprising a hedgehog therapeutic and a neurotrophic factor.

2. **(Reiterated)** The method of claim 1, wherein the hedgehog therapeutic comprises a full length mature hedgehog polypeptide or a bioactive fragment of a hedgehog polypeptide.

a² 3. **(Amended)** The method of claim 2, wherein the the hedgehog polypeptide comprises residue 24-197 of SEQ ID No. 15, residues 28-202 of SEQ ID No. 16 or residues 23-198 of SEQ ID No. 17.

4. **(Reiterated)** The method of claim 2, wherein the hedgehog therapeutic comprises a naturally occurring hedgehog polypeptide or a naturally occurring bioactive fragment thereof.

a³ 6. **(Amended)** The method of claim 1, wherein the cholinergic neuron is a cholinergic neuron of the basal forebrain.

a⁴ 10. **(Amended)** The method of claim 1, wherein the neurotrophic factor is selected from IGF-1, active truncated derivatives of IGF-1, aFGF, bFGF, PDGF, GDNF, NT-3 and NT-4/5.

11. **(Amended)** The method of claim 1, wherein the neurotrophic factor comprises NGF.

12. **(Reiterated)** The method of claim 11, wherein the neurotrophic factor consists essentially of NGF.

13. (Amended) The method of claim 1, wherein the neurotrophic factor comprises BDNF or CNTF.

14. (Amended) The method of claim 13, wherein the neurotrophic factor consists essentially of at least one of BDNF or CNTF.

The amended claims are restated below to reflect changes with respect to the last filing.

1. (Amended) A method of promoting differentiation or survival of a cholinergic neuron, ameliorating neuronal degeneration in a subject comprising administering to the subject a trophic amount of a composition comprising a hedgehog therapeutic and a neurotrophic factor.

3. (Amended) The method of claim 2, wherein the ~~sequence of the hedgehog polypeptide therapeutic~~ comprises at least the sequence of residue 24-197 of SEQ ID No. 15, residues or residues 28-202 of SEQ ID No. 16 or residues 23-198 of SEQ ID No. 17.

6. (Amended) The method of claim 1, wherein ~~there is neuronal degeneration of the cholinergic neuron~~ is a cholinergic neuron ~~neurons~~ of the basal forebrain ~~of the subject~~.

10. (Amended) The method of claim 1, wherein the ~~composition comprises a~~ neurotrophic factor is selected from the group consisting of IGF-1, active truncated derivatives of IGF-1 thereof, aFGF, bFGF, PDGF, GDNF, NT-3 and NT-4/5.

11. (Amended) The method of claim 1, wherein the ~~composition~~ neurotrophic factor comprises NGF.

13. (Amended) The method of claim 1, wherein the ~~composition~~ neurotrophic factor comprises BDNF or CNTF.

14. (Amended) The method of claim 13, wherein the neurotrophic factor consists essentially of at least one of BDNF; or CNTF or a mixture thereof.

REMARKS

Claims 1-28 constitute the pending claims in the present application, and Applicants elect with traverse inventions of Group I, claims 1-4 and 6-14. Applicants cancel, without prejudice, claims 7-9. If any clarification of the above response would facilitate prosecution of this application, Applicants respectfully request that the Examiner contact the undersigned at 617-951-7000. Should an extension of time be required, Applicants hereby petition for same and